Replies to post #213423 on Biotech Values

[n4807g]

The DSMB (Data Safety Monitoring Board) met on August 28 and recommended lowering the dose to 6.25x104 UCART123 cells per kilogram in both studies and capping cyclophosphamide to a total dose of 4g over 3 days.

An unfortunate event. I think the trial will be allowed to continue with adjustments suggested by the DSMB.

Haven't heard any updates on the ongoing UCART19 trial. I assume they've dosed patients........

JUNO dropped their lead drug due to patient deaths and currently is valued at 4.5 billion.

[DewDiligence]

CLLS CMO leaves to pursue other opportunities—perhaps a consequence of UCART123 clinical hold:

https://finance.yahoo.com/news/mathieu-simon-m-d-cellectis-203000933.html

[DewDiligence]

FDA lifts clinical hold on CLLS’ UCART123 programs:

https://finance.yahoo.com/news/fda-lifts-clinical-hold-cellectis-000000014.html